about
Acute treatment with relaxin protects the kidney against ischaemia/reperfusion injuryRelaxin does not improve Angiotensin II-induced target-organ damage.Relaxin causes selective outward remodeling of brain parenchymal arterioles via activation of peroxisome proliferator-activated receptor-γ.Dupuytren's: a systems biology disease.Cloning, expression, and functional characterization of relaxin receptor (leucine-rich repeat-containing g protein-coupled receptor 7) splice variants from human fetal membranes.The Anti-fibrotic Actions of Relaxin Are Mediated Through a NO-sGC-cGMP-Dependent Pathway in Renal Myofibroblasts In Vitro and Enhanced by the NO Donor, Diethylamine NONOate.Relaxin and atrial natriuretic peptide pathways participate in the anti-fibrotic effect of a melon concentrate in spontaneously hypertensive rats.Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.Characterization of relaxin receptor (RXFP1) desensitization and internalization in primary human decidual cells and RXFP1-transfected HEK293 cellsRelaxin and its role in the development and treatment of fibrosis.Renal tubulointerstitial fibrosis: common but never simple.Evidence-based management of rapidly progressing systemic sclerosis.Does serelaxin treatment alter passive mechanical wall properties in small resistance arteries?Human relaxin gene expression delivered by bioreducible dendrimer polymer for post-infarct cardiac remodeling in rats.Gene duplication and positive selection explains unusual physiological roles of the relaxin gene in the European rabbit.
P2860
Q33982388-BF4FFDFA-E295-4BCD-826B-305C9B8D6352Q35141812-9F786172-F93F-467B-A90C-C900F2583550Q35169517-DA386EBC-7100-41E2-B715-4C9C7EFF6970Q35840713-96102AC1-BBD6-46C0-8226-910DA779912FQ36509796-33CDC710-E364-46C9-A89E-252FA6BD0D58Q36749450-5FA70C8F-4967-4234-934D-77BBDFDEB8D0Q36799613-BFBEB280-B66F-485D-A259-DB808DECF52CQ37013037-799E6413-9861-4E2D-9F7A-329EEA51E673Q37147122-E6F26EEF-9118-4341-95FD-A66F20980095Q37165951-0A3B728E-1007-4621-B77C-5C43FBB44EEEQ37229308-253CAD48-6A05-4332-ADDD-697F4F66576FQ37368710-7ABF0874-8CDF-4F5C-AA5F-CECD4A1EE136Q37763779-4C4D0618-5AC9-42E8-898B-6E8E5D4A296DQ38960703-21AFFA2D-E02C-4530-88CB-947D2531B03AQ41762985-04552CD8-0E2B-419E-ABB3-01CCA94BB92EQ51418822-78833295-198B-41D0-BEBD-227B4C9B24E4
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Relaxin in cardiovascular and renal disease.
@ast
Relaxin in cardiovascular and renal disease.
@en
type
label
Relaxin in cardiovascular and renal disease.
@ast
Relaxin in cardiovascular and renal disease.
@en
prefLabel
Relaxin in cardiovascular and renal disease.
@ast
Relaxin in cardiovascular and renal disease.
@en
P356
P1433
P1476
Relaxin in cardiovascular and renal disease
@en
P2093
P2888
P304
P356
10.1038/SJ.KI.5000264
P407
P50
P577
2006-05-01T00:00:00Z